Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

PURPOSE: To determine the dose of cetuximab that can be safely combined with irinotecan for treatment of pediatric and adolescent patients with refractory solid tumors. PATIENTS AND METHODS: This open-label, phase I study enrolled patients ages 1 to 18 years with advanced refractory solid tumors, in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Trippett, Tanya M., Herzog, Cynthia, Whitlock, James A., Wolff, Johannes, Kuttesch, John, Bagatell, Rochelle, Hunger, Stephen P., Boklan, Jessica, Smith, Amy A., Arceci, Robert J., Katzenstein, Howard M., Harbison, Christopher, Zhou, Xiaofei, Lu, Haolan, Langer, Christiane, Weber, Martin, Gore, Lia
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321093/
https://ncbi.nlm.nih.gov/pubmed/19770383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.8975
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados